Sign in
EFTR Stock Price, Chart, Stats & News
eFFECTOR Therapeutics, Inc.
Save
eFFECTOR Therapeutics, Inc. (EFTR) does not currently pay a dividend.
941
Market cap
–
Current P/E
–
Forward P/E
EFTR chart
About
Health care
Sector
Biotechnology
Industry
eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is currently undergoing a Phase 2b clinical study for patients diagnosed with metastatic non-small cell lung cancer.
Similar securities
Based on sector and market capitalization
Report issue